Valuation: Black Diamond Therapeutics, Inc.

Market Cap 107M 93.89M 87.16M 80.09M 151M 10.34B 153M 1.04B 406M 5.06B 402M 394M 17.48B P/E 2026 *
-2.89x
P/E 2027 * -1.86x
Enterprise Value 107M 93.89M 87.16M 80.09M 151M 10.34B 153M 1.04B 406M 5.06B 402M 394M 17.48B EV / Sales 2026 *
19.3x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day-2.14%
1 week+1.10%
Current month-1.08%
1 month+13.66%
3 months-45.37%
6 months-30.94%
Current year-24.69%
1 week 1.76
Extreme 1.76
1.9
1 month 1.6
Extreme 1.6
2.22
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.47
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Date Insider Type Main position Quantity % Market Cap.
6/26/26 Free

Director

40,000 0.0698%
6/26/26 Free

Director

40,000 0.0698%
6/26/26 Free

Director

40,000 0.0698%
Change 5-day change 1-year change 3-year change Capi.($)
-2.14%+1.10%-42.63%-51.33% 107M
-0.43%-1.26%+52.13%+85.69% 55.57B
-0.24%-0.37%+57.02%+54.21% 54.26B
-0.54%-0.17%-17.60%-14.20% 23.35B
-1.82%-2.89%+3.61%+421.21% 23.54B
+0.05%+1.68%+38.71%-4.57% 20.32B
+3.16%+2.74%+37.33%-31.36% 17.36B
+1.08%+3.77%+36.92%+593.96% 15.59B
+0.43%-1.67%+166.53%+299.61% 14.96B
-2.03%-1.03%+23.63%+176.42% 14.11B
Average -0.25%-0.15%+35.57%+152.96% 23.92B
Weighted average by Cap. -0.18%-0.23%+43.88%+137.47%

Financials

2026 *2027 *
Net sales 5.56M 4.87M 4.52M 4.15M 7.82M 536M 7.94M 53.83M 21.07M 262M 20.86M 20.41M 906M -
Net income -40.47M -35.46M -32.92M -30.25M -57.01M -3.91B -57.84M -392M -154M -1.91B -152M -149M -6.6B -70.04M -61.37M -56.98M -52.36M -98.66M -6.76B -100M -679M -266M -3.31B -263M -257M -11.42B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-07-22 US$1.830 -2.14% 516,453
26-07-21 US$1.870 +3.31% 490,389
26-07-20 US$1.810 +1.12% 695,830
26-07-17 US$1.790 -1.10% 708,209
26-07-16 US$1.810 0.00% 855,858
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.870USD
Average target price
9.857USD
Spread / Average Target
+427.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock